The $1B Merck-Bayer drug that divided cardiologists in March gets priority review
Three months after Merck published in the New England Journal of Medicine data that left doctors and investors divided over just how well its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
